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Purpose: To compare the efﬁ  cacy of  brinzolamide in Japanese patients with primary open-angle 
glaucoma (POAG) or ocular hypertension (OH) after a change from timolol in combination 
therapy with latanoprost.
Methods: A 12-week, prospective, open-label, comparative study was performed in 20 patients 
[11 males and 9 females, mean age of 64.5 ± 11.0 (SD)y] with POAG or OH treated with 
both latanoprost once daily and timolol 0.5% twice daily. During the study brinzolamide was 
substituted for timolol. Intraocular pressure (IOP) was measured at baseline, 4, 8, and 12 weeks. 
Blood pressure (BP), pulse rate (PR), and adverse events were also recorded.
Results: IOPs at baseline, 4, 8, and 12 weeks were 18.6 ± 2.1 mmHg, 17.8 ± 2.6 mmHg, 
17.4 ± 2.5 mmHg, and 17.3 ± 3.5 mmHg, respectively. IOP reduction at 4 and 8 weeks was 
statistically signiﬁ  cant (p  0.05). The PR was signiﬁ  cantly increased at 12 weeks (p  0.01), 
but BP was not signiﬁ  cantly affected. Four ocular adverse events were noted, but all were mild 
and transient.
Conclusions: Substituting brinzolamide 1% for timolol 0.5% in combination therapy with 
latanoprost 0.005% demonstrated signiﬁ  cant IOP reduction with improvement in PR with 
POAG or OH. Combination therapy using latanoprost and brinzolamide may be recommended 
for better IOP control with fewer systemic adverse events.
Keywords: open-angle glaucoma, brinzolamide/latanprost combination therapy, timolol/
latanoprost combination therapy, intraocular pressure
Introduction
In recent years, signiﬁ  cant advances have been achieved in the development of topical 
glaucoma medications (Camras et al 1996; Silver 1998; Brubaker et al 2000), and 
options for combination therapy have increased. Because a signiﬁ  cant proportion 
of glaucoma patients eventually need more than one agent for adequate control of 
intraocular pressure (IOP) (Kobelt-Nguyen et al 1998), it is important to reduce 
adverse ocular or systemic events in those treated with combination therapy. Using 
prostaglandin analogs as ﬁ  rst-line treatment has given rise to numerous studies in 
search for the most effective and best-tolerated combination, from both a local and a 
systemic perspective. IOP reduction rates with various agents have been reported as Clinical Ophthalmology 2008:2(4) 704
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follows: timolol 0.5% monotherapy, approximately 23.4% 
(Schenker et al 1999); topical carbonic anhydrase inhibitors 
(CAIs) such as brinzolamide, 13.2%–16.7% (Sall 2000); 
and dorzolamide, 19.4% (Arici et al 1998). Meta-analysis 
of the IOP-lowering effects of several glaucoma medica-
tions demonstrated similar results (van der Valk 2005), 
with IOP reduction rates being highest with beta-blockers. 
The combination of a prostaglandin analog plus a beta-
blocker has been extensively studied and is probably the 
most commonly used combination (Alm et al 1995; Larsson 
2001; Higginbotham et al 2002). It is noteworthy that the 
addition of a topical beta-blocker to latanoprost provides a 
slight additional IOP reduction (Bucci 1999; O’Connor et al 
2002). The efﬁ  cacy of combination therapy using a topical 
CAI and latanoprost has not been studied to the same extent 
as that of latanoprost in combination with a beta-blocker; 
however, dorzolamide and brinzolamide have been reported 
to lower IOP at least as effectively as a beta-blocker when 
added to latanoprost (O’Connor et al 2002; Shoji 2005). This 
option of latanoprost and topical CAI combination therapy 
may confer advantages for glaucoma patients as both drugs 
present an excellent systemic safety proﬁ  le.
Brinzolamide (1% ophthalmic solution) is a topical CAI 
that, like dorzolamide, is known to lower IOP by inhibiting 
the production of aqueous humor (Silver 1998; Schenker 
et al 1999; Brubaker et al 2000; DeSantis 2000; March and 
Ochsner 2000; Michaud and Friren 2001). The IOP-lowering 
effect of brinzolamide 1.0% is reported to be equivalent to 
that of dorzolamide 2%, both as monotherapy (Barnebey 
and Kwok 2000; Sall 2000) and in combination therapy 
with timolol (Michaud and Friren 2001). Furthermore, 
when brinzolamide is substituted for dorzolamide, IOP is 
further decreased (Barnebey and Kwok 2000) or is equal to 
IOP before substitution (Kobayashi et al 2004; Kubota et al 
2004). In evaluations of ocular adverse events, dorzolamide 
has reportedly caused more intense ocular irritation than 
brinzolamide (Barnebey and Kwok 2000; Sall 2000; Silver 
2000; Michaud and Friren 2001; Seong et al 2001; Kobayashi 
et al 2004; Stewart et al 2004; Tsukamoto et al 2005). The 
incidence of ocular discomfort or blurred vision for brinzol-
amide is signiﬁ  cantly higher than that of dorzolamide in one 
study (Silver 2000), but not statistically signiﬁ  cant in other 
studies (Sall 2000; Michaud and Friren 2001; Stewart et al 
2004; Tsukamoto et al 2005). Thus brinzolamide 1% twice 
daily was selected as the topical CAI in this study.
The objective of this study was to evaluate the effects 
of a change in therapeutic regimen from combination 
therapy with timolol/latanoprost to combination therapy with 
brinzolamide/latanoprost in terms of: IOP, the cardiovascular 
functions of blood pressure (BP) and pulse rate (PR), and 
ocular adverse events.
Patients and methods
A 12-week, open-label, non-randomized, prospective, 
comparative study was conducted in Japanese patients with 
primary open-angle glaucoma (POAG) (17 patients) or ocular 
hypertension (OH) (3 patients) at Ryukyu University Hospital 
and Yamagata University Hospital. POAG was deﬁ  ned as 
glaucomatous optic neuropathy with repeatable visual ﬁ  eld 
defects, and open angle. OH was deﬁ  ned as a normal visual 
ﬁ  eld and normal optic disc appearance. Enrolled patients had 
been under treatment with both latanoprost (once daily, at 
8 PM) and timolol 0.5% (twice a day, at 8 AM and 8 PM) 
for 3 months or longer and had not used any topical CAI 
prior to this study.
Inclusion criteria for the study were: (1) patients with 
primary open-angle glaucoma or ocular hypertension, 
(2) patients who had been treated with both latanoprost 
0.005% once daily and timolol 0.5% twice daily for more than 
3 months, (3) patients with IOP on latanoprost and timolol 
treatment 16 mmHg, (4) patients aged 20 years or over. 
The study included both males and females and inpatients 
and outpatients.
The following patients were excluded from the 
study: (1) patients with a history of chronic or recurrent 
inﬂ  ammatory eye disease, ocular trauma, or ocular infection 
within the past 3 months, (2) those with corneal abnormalities 
preventing reliable applanation tonometry, (3) those who had 
had intraocular surgery, (4) those who had had laser surgery 
within the past 3 months, (5) those with severe, unstable, 
or uncontrolled cardiovascular or pulmonary disease that 
would preclude use of an ophthalmic beta-blocker, (6) those 
currently using any ophthalmic, dermatologic, or systemic 
corticosteroid or oral CAIs, (7) those with a history of severe 
hypersensitivity to oral CAIs, sulfonamide drugs, or any 
components of these medications, (8) those with dementia, 
and (9) those whom the investigator determined ineligible 
to participate in this study. Because enrolled patients were 
eligible for latanoprost and timolol combination therapy, 
those with hypersensitivity or allergy to either of these agents 
were excluded prior to the study.
The study protocol followed the guidelines of the 
Declaration of Helsinki. All patients were given a thorough 
explanation of the aims, protocol, and all procedures of the 
study before enrollment, and informed consent was then 
obtained.Clinical Ophthalmology 2008:2(4) 705
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Binzolamide 1% twice daily (at 8 AM and 8 PM) was 
given to each patient in place of timolol 0.5% twice daily 
to compare the efﬁ  cacy and side effects from this change in 
therapeutic regimen. There was no wash-out period between 
the two treatment regimens. The prescription of brinzolamide 
1% twice a day is common practice and is based on the label 
approved by the government in Japan.
IOP was analyzed on 1 eye per patient. If both eyes 
were eligible for inclusion, the eye with higher baseline 
IOP was selected as the study eye. When IOP was the same 
in both eyes, the right eye was selected. IOP was measured 
at the baseline visit and at 4, 8, and 12 weeks after enroll-
ment using Goldmann applanation tonometry. The time of 
day at which IOP was measured during the study was the 
same as that at baseline. IOP measured immediately prior 
to substituting brinzolamide 1% was considered as the 
baseline. Resting BP (systolic and diastolic) and PR were 
also measured at the baseline and at 12 weeks. All patients 
underwent ophthalmic examinations at each visit during 
the follow-up period. Subjective ocular discomfort (mild 
irritation, blurred vision, and conjunctival hyperemia) 
and subjective ocular adverse events (stinging/intense 
irritation) after instillation of eye drops were investigated 
by patient interview. During clinic visits patients were 
asked whether they had a sense of ocular discomfort at 
the time of instillation and how long the ocular discomfort 
persisted after instillation. If a patient complained of any 
sense of irritation and/or blurred vision at least once during 
the follow-up period, the patient was regarded as having 
ocular discomfort.
IOP, BP, and PR values are shown as mean ± standard 
deviation. The Wilcoxon signed rank test was used for 
statistical analysis, and the difference was considered 
signiﬁ  cant when the p value was less than 0.05.
Results
Of the 20 patients (11 males and 9 females) enrolled, no 
patients dropped out during the course of the study, and 
therefore 20 patients were accepted for analysis of IOP 
and local and systemic adverse events. Table 1 shows the 
demograhpic characteristics of the patients. Brieﬂ  y, the 
mean age of the patients was 64.5 ± 11.0 (mean ± standard 
deviation) years old. Seventeen patients (17 eyes) had 
POAG, and 3 patients (3 eyes) had OH. All had been 
treated with a combination of latanoprost 0.005% and 
timolol 0.5% for more than 3 months. Figure 1 shows 
the course of IOP at baseline and after the regimen 
change. Mean IOP at baseline, 4, 8, and 12 weeks after 
enrollment were 18.6 ± 2.1 mmHg, 17.8 ± 2.6 mmHg, 
17.4 ± 2.5 mmHg, and 17.3 ± 3.5 mmHg, respectively. 
Signiﬁ  cant reductions in mean IOP were observed at the 
4-week and 8-week time points (p  0.05) (Figure 2). 
Mean IOP reduction from baseline was 0.8 mmHg (4.3% 
reduction) after 4 weeks, 1.2 mmHg (6.5% reduction) after 
8 weeks, and 1.3 mmHg (7.0% reduction) after 12 weeks.
Mean systolic and diastolic BPs were 139 ± 20 mmHg 
and 80 ± 12 mmHg at baseline, and 135 ± 24 mmHg and 
81 ± 13 mmHg at the 12-week point. Thus the substitution 
of brinzolamide had little effect on systolic and diastolic BP 
(p  0.05) (Figure 3).
In contrast, mean PR was 68 ± 9 bpm at baseline, with 
a signiﬁ  cant increase to 78 ± 13 bpm at the 12-week point 
(p  0.01) (Figure 4). Visual ﬁ  eld defect and optic disc 
appearance did not change throughout the study period.
No patient reported the adverse event of intense ocular 
irritation. After therapeutic substitution, ocular adverse 
events were observed in 4 cases (2 blurred vision, 1 mild 
irritation, and 1 mild hyperemia) (Table 2). All were mild and 
transient and disappeared without any treatment. Systemic 
adverse events were not observed.
Discussion
In this study, we compared the efficacy and safety of 
brinzolamide 1% twice daily as a second-line medication 
Figure 1 Change in IOP after regimen change. (**p < 0.05, Wilcoxon signed rank test).
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Table 1 Patients
Glaucoma diagnosis
  Primary open angle glaucoma 17 eyes
  Ocular hypertension 3 eyes 
Female : Male 9 : 11
Age (Mean ± standard deviation)  64.5 ± 11.0 yearsClinical Ophthalmology 2008:2(4) 706
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when substituted for timolol 0.5% in combination therapy 
with latanoprost in Japanese patients with POAG or 
OH. We concluded that substitution of brinzolamide 
for timolol significantly lowered IOP with significant 
improvement of PR without systemic or serious local 
adverse reactions.
Efﬁ  cacy
Two recently developed topical CAIs, dorzolamide and 
brinzolamide, are now usually used as an adjunctive 
therapy to other anti-glaucoma eye drops. The IOP-lowering 
effect of brinzolamide 1% (twice daily) was equivalent to 
dorzolamide 2% (3 times daily) when added to timolol 0.5% 
(Michaud and Friren 2001). The effect of topical CAIs as a 
second-line medication has been reported (Arici et al 1998; 
Shin 2000; Michaud and Friren 2001; O’Connor et al 
2002; Martinez-de-la-Casa et al 2004; Shoji et al 2005; 
Tsukamoto et al 2005). Brinzolamide was reported to show 
an additional IOP reduction of 5.3 mmHg (23.5%) when 
added to latanoprost (Shoji et al 2005). It has also been 
reported that the addition of dorzolamide to latanoprost 
decreased IOP by 3.9 mmHg (19.7%) compared with 
beta-blocker (2.5 mmHg; 12.3%) (O’Conner et al 2002). 
Brinzolamide showed similar efﬁ  cacy to timolol maleate 
when added to travoprost (Hollo et al 2006). In our study, 
IOP reductions from baseline at 4, 8, and 12 weeks after 
the substitution of brinzolamide 1% for timolol 0.5% were 
0.8, 1.2, and 1.3 mmHg, respectively. The patients who 
enrolled in this study had already undergone treatment 
with latanoprost 0.005% and timolol 0.5%. Nevertheless, 
the substitution of brinzolamide for timolol 0.5% further 
signiﬁ  cantly decreased IOP. This result was similar to the 
IOP reduction observed by O’Conner et al (2002). The Early 
Manifest Glaucoma Trial Group reported that on follow-up, 
each mmHg reduction in IOP decreased the risk of disease 
progression by approximately 10% (Heijl et al 2002). There-
fore, even though the reduction in IOP after the substitution   
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Figure 3 Change in blood pressure after regimen change. No signiﬁ  cant differences 
were seen in blood pressure (p > 0.05, Wilcoxon signed rank test).
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Figure 2 Change in IOP reduction rate after regimen change.  Average IOP reduction 
rate 12 weeks after regimen change was 7.3%.
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Figure 4 Change in pulse rate after regimen change. The pulse rate was signiﬁ  cantly 
increased 12 weeks after substituting brinzolamide compared with baseline with 
timolol (*p < 0.01, Wilcoxon signed rank test).
Table 2 Ocular discomfort
Blurring  2 eyes (10%)
Irritation (mild) 1 eye (5%)
Hyperemia (mild) 1 eye (5%)
Systemic adverse events were not observed.Clinical Ophthalmology 2008:2(4) 707
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of brinzolamide for timolol was small (2 mmHg), this IOP 
reduction could be considered clinically signiﬁ  cant.
Ocular discomfort
The occurrence of ocular discomfort is related to the formula 
used for ophthalmic solutions. Brinzolamide is a white suspen-
sion. In our study, brinzolamide caused blurred vision (2 cases), 
and mild irritation and mild hyperemia (1 case) after switching 
from timolol. As with earlier studies, adverse events related to 
brinzolamide treatment generally occurred on instillation, were 
usually mild, resolved without treatment, and generally did 
not interrupt therapy continuation (Silver 1998; Barnebey and 
Kwok 2000; Martinez-de-la-Casa et al 2004) (ie, no patient was 
discontinued from the current study due to adverse events). It 
has also been reported that in comparisons of brinzolamide and 
timolol monotherapy (March and Ochsner 2000), brinzolamide 
produced fewer (3.3%) ocular adverse events (burning/stinging) 
than timolol (8.0%). The ocular discomfort of blurred vision 
was generally mild, and the medication was well tolerated. 
Therefore, evidence suggests that substituting brinzolamide 
for timolol may produce very few ocular adverse events in 
combination therapy with latanoprost.
Systemic effects
Non-selective and selective beta-blockers may have signiﬁ  -
cant side effects on cardiovascular and respiratory organs, 
especially in elderly populations (Nelson et al 1986). 
When assessing a drug like timolol, which is used by a 
predominantly elderly population that is a priori at risk for 
cardiovascular and respiratory disease, it is often difﬁ  cult 
to determine whether the suspect event is a consequence of 
the drug, the patients’ age, an underlying medical condition, 
or a combination of factors. In agreement with a previous 
study, no clinically signiﬁ  cant adverse effect on PR and BP 
occurred with brinzolamide (Silver 1998) and no systemic 
side effects were noted. Furthermore, increased PR is a 
potentially beneﬁ  cial effect when substituting brinzomalmide 
for timolol. Topical beta-blockers can cause nocturnal hypo-
tension in glaucoma patients (Heyreh et al 1999). Glaucoma 
is a disease that generally requires lifelong treatment. The 
most effective medications for long-term therapy are those 
that are efﬁ  cacious, well tolerated, and show few side effects. 
In those patients in whom beta-blockers are contraindicated, 
brinzolamide offers an effective alternative.
Conclusion
The latanoprost/brinzolamide combination can have a 
signiﬁ  cant additive effect on IOP reduction compared with 
the latanoprost/timolol combination. IOP reduction has been 
established to be an effective means of treating glaucoma 
(Mao et al 1991; Collaborative Normal-Tension Glaucoma 
Study Group 1998; AGIS Investigations 2000; Heijl et al 
2002; Kass 2002; Tsukamoto et al 2005). To improve quality 
of life and vision, and to reduce the adverse events of glau-
coma treatment, it is necessary to achieve a maximum IOP 
reduction with a minimum but adequate number of instilla-
tions. Substitution of brinzolamide 1% for timolol 0.5% in 
combination therapy with latanoprost 0.005% demonstrated 
superior and signiﬁ  cant IOP reduction and improvement 
of PR. The ocular discomforts of blurred vision in 2 cases, 
mild irritation in 1 case, and mild hyperemia in 1 case were 
transient and mild after regimen change, and all resolved 
without treatment. The use of brinzolamide in place of timolol 
as a second-line medication in combination with latanoprost 
can be recommended for POAG or OH patients for better 
IOP control and fewer systemic side effects. However, this 
open non-randomized study evaluated a limited number 
of the patients treated in the short term, so that additional 
randomized studies on long-term administration and diurnal 
IOPs need to be considered.
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